Scott M Dehm
Faculty, Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (56)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Purpose: Androgen receptor pathway inhibitors (ARPI), such as enzalutamide and abiraterone, are standard treatments for metastatic castration-resistant prostate cancer (mCRPC). However, a subset of patients display primary resistance and most eventually acquire secondary resistance. This study aimed to define genomic features of ARPI resistance using longitudinal ctDNA analysis. Experimental Design: We used the targeted AR-ctDETECT cell-free DNA (cfDNA) sequencing assay to profile tumor-derived genomic alterations in plasma samples collected at baseline and progression from patients with mCRPC enrolled in the phase III Alliance A031201 trial of first-line enzalutamide with or without abiraterone. Analysis focused on 327 patients with paired samples available from both time points. Results: Progression plasma samples displayed elevated cfDNA levels and increased ctDNA positivity. AR was the most frequently altered gene at baseline and at progression. AR copy-number gains and AR genomic structural rearrangements (AR-GSR) increased at progression, along with copy-number losses of FANCA, POLD1, RAD54L, CDKN2A, ZNRF3, and ETS2. An AR extrachromosomal DNA signature was enriched at progression and was associated with AR-GSRs predicted to truncate the AR ligand-binding domain. Stratification by two extremes of radiographic progression-free survival revealed preferential accumulation of AR alterations in patients with delayed progression and a higher burden of non-AR alterations in patients with rapid progression. Conclusions: AR alterations in ctDNA accumulate at progression in patients with mCRPC treated with ARPIs, especially in those with initially durable responses. These findings support the use of liquid biopsy to serially track resistance mechanisms and inform precision therapy in advanced prostate cancer.
Year:
2026
Year:
2026
Year:
2026
Purpose: Germline alterations in homologous recombination repair (gHRR) genes affect the pathogenesis, treatment options, and survival of patients with cancer. However, distinct gHRR gene alterations may differentially affect treatment response and oncogenic signaling. In this study, we interrogated genomic and transcriptomic data and assessed clinical outcomes of patients with gHRR mutations across four BRCA-associated cancers (breast, ovarian, pancreatic, and prostate cancers) to identify therapeutic vulnerabilities. Experimental Design: We assessed 24,309 patients undergoing matched tumor/normal next-generation DNA and RNA sequencing. Annotated gHRR gene variants [germline BRCA1, germline BRCA2, germline PALB2, germline ATM (gATM), and germline CHEK2] were analyzed. HRs were used to assess survival outcomes comparing germline versus sporadic groups. Somatic alterations and their frequencies were compared across gHRR-altered groups. Differential gene expression and gene set enrichment analysis were used to compare transcriptomic profiles. Results: Somatic TP53 mutations were depleted in gATM carriers (P < 0.05) across all four BRCA-associated cancers by up to 2.5-fold. Tumors with germline BRCA1/2 mutations were associated with improved survival in patients with ovarian cancer and had consistent enrichment of TP53 mutations in all four cancers. gATM mutations displayed elevated p53 transcriptional activity in all four cancers, with significance reached in breast and prostate cancers (P < 0.01). In breast, ovarian, and prostate cancers, gATM tumors demonstrated significantly increased inflammatory pathways (P < 0.001). Finally, using gene dependency data, we found that cell lines that were highly dependent on ATM were co-dependent on canonical p53 function. Conclusions: gATM-associated cancers seem to require intact p53 activity and this synthetic essentiality may be used to guide targeted therapies that perturb canonical TP53 function.
Year:
2025
The roles of nucleoplasm-residing nucleoporins (NUP) in solid tumors, including prostate cancer, remain unknown. In this study, we reveal the clinical significance and mechanistic role of the off-pore NUP, soluble POM121 (sPOM121), as a crucial transcriptional regulator that enhances the aggressiveness of metastatic prostate cancer. Using orthogonal methodologies in human samples, sPOM121 was identified as the predominantly expressed nucleoplasmic NUP in prostate cancer. Unbiased proteomic and epigenomic studies demonstrate that sPOM121, through its C-terminus, interacts with the chromatin remodeler SMARCA5 at gene promoter sites and localizes at nuclear condensates, reprogramming gene expression. Indeed, sPOM121 regulates a distinct oncogenic gene network, including β-catenin, leading to prostate cancer progression and immune evasion. Importantly, targeting the sPOM121/β-catenin axis in patient-derived preclinical and syngeneic mouse models halts prostate cancer aggressiveness and enhances antitumor immunity. Taken together, these findings reveal previously unknown actionable reprogramming functions of off-pore NUPs in solid tumors. Significance: This study uncovers how oncogenic signaling programs are transcriptionally heightened by the NUP sPOM121 in metastatic prostate cancer. Localization of sPOM121 at active transcriptional nuclear condensates propels disease progression and immune evasion, offering novel anticancer therapeutic opportunities.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (71)
Alexander Tsai
Assistant Professor
University of Minnesota
Qingshu Meng
Research Assistant Professor
Northwestern University Feinberg School of Medicine
Yvette Soignier
University of Minnesota Twin Cities
Weibo Cai
University of Wisconsin-Madison
Andrew Armstrong
Professor
Duke Cancer Institute
Oliver Sartor
Tulane University School of Medicine
Laura Kotz
University of Minnesota Twin Cities
John Lozada
University of Rochester Medical Center
George Sledge
-
Grace Blitzer
University of Wisconsin-Madison
Philippa Kennedy
Faculty, Assistant Professor
University of Minnesota
Joshua Lang
Professor
University of Wisconsin-Madison
Natalie Reizine
Assistant Professor
University of Chicago
Luke Selth
Associate Professor in Medical Sciences
Flinders University
Geraldine Laven-Law
Flinders University
Jason M. Sheltzer
Stanford University
Scott Tagawa
Weill Cornell Medicine
Emil Lou
University of Minnesota
Ari VanderWalde
Global Head of Clinical Trials
-
Dang Nguyen
Faculty, Assistant Professor
University of Minnesota
Eugene Shenderov
Associate Professor
Johns Hopkins University School of Medicine
HAMID EMAMEKHOO
University of Wisconsin-Madison
Rendong Yang
Associate Professor
Northwestern University Feinberg School of Medicine
Haojie Huang
Professor
Mayo Clinic College of Medicine and Science
Steven Kregel
Assistant Professor
Loyola University Chicago
Justin Hwang
Associate Professor
University of Minnesota
Shuang G. Zhao
University of Wisconsin-Madison
Liguo Wang
Professor of Biomedical Informatics
Mayo Clinic Minnesota
Bin Luo
Assistant Professor
Kennesaw State University
Siddhartha Yadav
Associate Professor of Oncology
Mayo Clinic
Veronica Rodriguez-Bravo
Associate Professor
Mayo Clinic
Shijia Zhu
Assistant Professor
University of Minnesota
Catherine Marshall
Associate Professor
Johns Hopkins University School of Medicine
Rohan Garje
Clinical Associate professor
Iowa State University
Luke Gaughan
Reader in Molecular Oncology
Newcastle University
Elisabeth I. Heath
Wayne State University School of Medicine
Raj Kumar Shrestha
Research Associate
Flinders University
Susan Halabi
Duke University
David Kosoff
University of Wisconsin-Madison
Josep Domingo-Domenech
Professor
Mayo Clinic
Jonathan W Engle
Associate Professor
University of Wisconsin-Madison
Menggang Yu
Professor
University of Michigan
Haidong Dong
Professor/Consultant
Mayo Clinic Rochester
Jacob Orme
Assistant Professor
Mayo Clinic
Martin Felices
Associate Professor
University of Minnesota
Xianghua Luo
Professor
University of Minnesota
Marina N Sharifi
Assistant Professor
University of Wisconsin-Madison
Manish Kohli
Professor
Huntsman Cancer Institute
Emmanuel Stylianos Antonarakis
Professor of Medicine, Associate Director for Translation
-
Mitchell G Lawrence
-
Emmanuel S. Antonarakis
-
Carly Miller
University of Minnesota
Jeffrey S Miller
University of Minnesota System
Felix Y. Feng
University of California
Mukesh Pandey
Professor of Radiology
Mayo Clinic
Luke Hoeppner
Faculty, Associate Professor
University of Minnesota
Atish Choudhury
Dana-Farber Cancer Institute
Erika Heninger
University of Wisconsin-Madison
Douglas Yee
Professor
University of Minnesota
Peter S. Nelson
Fred Hutchinson Cancer Research Center
TINGYOU WANG
Research Assistant Professor
Northwestern University Feinberg School of Medicine
Sk. Kayum Alam
Researchers, Research Professional 5
University of Minnesota
Nicholas Zorko
Assistant Professor
University of Minnesota
Neeraj Agarwal
Faculty Member
Dana-Farber Cancer Institute
Daniel P. Petrylak
-
Sabine Karam
Associate Professor of Medicine
University of Minnesota
Justin M. Drake
University of Minnesota
Rana R. McKay
University of California, San Diego
Dave Hoon
Principal Investigator
The Lundquist Institute
Ruping Sun
Assistant Professor
University of Minnesota
R. Stephanie Huang
Faculty, Professor
University of Minnesota
Make your next move.
Prepare your application
Review drafts before you send them.